In in vitro experiments, Direct Target HSF1 Inhibitor (DTHIB) treatment of prostate cancer cells dose-dependently inhibited the expression of molecular chaperones HSP70 and HSP40 and led to a reduction in AR and diminished prostate-specific antigen (PSA) expression, a marker for prostate cancer progression [31]. This evidence concerns the gene AR and prostate carcinoma.